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ABSTRACT
This study observes how an evidential reasoning approach can be used as a
diagnostic tool for early detection of pancreatic cancer. The evidential reasoning
model combines the output of a linear Support Vector Classifier (SVC) with factors
such as smoking history, health history, biopsy location, NGS technology used, and
more to predict the likelihood of the disease. The SVC was trained using genomic
data of pancreatic cancer patients derived from the National Cancer Institute (NIH)
Genomic Data Commons (GDC). To test the evidential reasoning model, a variety
of synthetic data was compiled to test the impact of combinations of different factors.
Through experimentation, we monitored how the evidential interval for pancreatic
cancer fluctuated based on the inputs that were provided. We observed how the
pancreatic cancer evidential interval increased and the machine learning prediction
of pancreatic cancer was supported when the input changed from a non-smoker and
non-drinker to an individual with a highly active smoking and drinking history.
Similarly, we observed how the evidential interval for pancreatic cancer increased
significantly when the machine learning prediction for pancreatic cancer was
maintained as high and the input of the quality of the sequencing read was changed
from a high quantity of cytosine guanine content and homopolymer regions to a
moderate quantity of cytosine guanine content and low homopolymer regions;
indicating that there was initially a higher likelihood of error in the sequencing reads,
resulting in a more inaccurate machine learning output. This experiment shows that
an evidence-based approach has the potential to contribute as a diagnostic tool for
screening for high-risk groups. Future work should focus on improving the machine
learning model by using a larger pancreatic cancer genomic database. Next steps
will involve programmatically analyzing real sequencing reads for irregular guanine
cytosine content and high homopolymer regions.
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Key Words: Next Generation Sequencing, Mutations, Homopolymer Regions,
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INTRODUCTION
Pancreatic cancer is an aggressive form of cancer that begins localized to the
pancreas, but due to lack of symptoms and limited detection options, the disease
goes undetected and spreads to other organs. Because tumors spread while remaining
undetected and treatment options are limited, pancreatic cancer has the lowest
survival rate of all cancers, with a 5-year survival rate of ~7% (Gharibi, Adamian,
& Kelber, 2016). Of all the types of pancreatic cancer, pancreatic ductal
adenocarcinoma (PDAC) is not only the most common, but also the most aggressive
and ranks as fourth in most cancer related deaths (Gharibi, Adamian, & Kelber,
2016).
PDAC is a complex form of pancreatic cancer with an average of 63 mutations per
tumor (Amin & DiMaio, 2016). PDAC forms as precursor lesions, known as
pancreatic intraepithelial neoplasia (PanIN). The source of PDAC is the cells of the
pancreatic duct (Stark & Eibl, 2015). Genetic mutations in the ductal epithelium are
the source of the development of the precursor lesions. The most scrutinized source
is the oncogenic KRAS gene. When the tumor suppressor genes CDKN2A, TP53,
and SMAD4 are deactivated, the ductal epithelium undergoes drastic
transformations causing lesions to worsen to grades 2 (G2) and 3 (G3); PDAC grades
G1 means the cancer looks similar to the healthy surrounding pancreatic tissue, G3
means the cancer tissue looks very abnormal, and G2 lies somewhere between G1
and G3 (Isaji, et al., 2018) (Amin & DiMaio, 2016).
Among new cases of PDAC, 51% and 49% are estimated to impact men and women
(Gharibi, Adamian, & Kelber, 2016). It is estimated that 83% of PDAC cases end in
death (Siegel, Miller, & Jemal, 2015). Age and ethnicity also play a hand in the
likelihood of developing PDAC. Nearly 27% of all new diagnoses are in the age

range of 75 and 84 and 9% are in the range of 45 and 54 years old (Howlader, et al.,
2016). Among ethnicities, African Americans are at highest risk of developing
PDAC with a probability of 15.7 out of 100,000, while Asian-Americans have the
lowest probability of 9.8 out of 100,000 (Howlader, et al., 2016).
Unfortunately, while the development and morbidity rates of other cancers decline,
pancreatic cancer continues to rise. Detecting pancreatic cancer early, while the
tumors have not metastasized, dramatically increases the likelihood of survival.
Unfortunately, only 9% of cases are detected during the early stage (Howlader, et
al., 2016). Even when diagnosed early, the 5-year survival rate is merely 26%, while
most other cancers have a much higher 5-year survival rate (Bachmann, Michalski,
Martignoni, Büchler, & Friess, 2006). For example, the 5-year survival rate for
breast and prostate cancer is 99%, 92% for the kidney, 90% for colon and rectum,
83% for oral cavity and pharynx, 64% for stomach, and 54% for lung and bronchus
(Gharibi, Adamian, & Kelber, 2016). Once pancreatic spreads, the 5-year survival
rate drops down to 10%, however, tumor detection rises to 28%. Once the tumors
reach more distant organs, the 5-year survival rate drops down to 2%, while the
likelihood of detection rises to 53% (Howlader, et al., 2016). Over the past 40 years,
5-year survival rates for a variety of cancers have increased significantly, while
pancreatic cancer has remained nearly the same, as shown in the Table I (Gharibi,
Adamian, & Kelber, 2016).
Table I
Past Vs. Present Survival Rates of Various Cancers

Cancer Type
1970's Survival Rate Current Survival Rate
Prostate Cancer
68%
>99%
Leukemia
34%
60%
Pancreatic Cancer
3%
7%
2

When tumors are still localized to the pancreas, surgery still provides the highest
chance of survival. In 2016 the reported median survival rate was 14-20 months and
the 5-year survival rate was up to 25% post-resection of the pancreas (Gharibi,
Adamian, & Kelber, 2016). Because of the unassuming nature of symptoms
associated with pancreatic cancer, tumors metastasize by the time they are detected
through imaging. Currently, diagnostic biomarkers are the focus of researchers as a
means of detecting the cancer in its early stages. The CA19-9 antigen is considered
the best pancreatic cancer biomarker; however, CA19-9 is not specific to pancreatic
cancer, and is known to result in false positives because it is detected in both benign
and malignant tumors (Gharibi, Adamian, & Kelber, 2016). Also, 10% of the
population cannot produce the protein (Gharibi, Adamian, & Kelber, 2016). Finding
a novel biomarker that is unique to pancreatic cancer would be a significant
advancement in early detection.

3

BACKGROUND
The difficulty in detecting pancreatic cancer is primarily due to the lack of
symptoms. Even in later stages, symptoms can be unassuming and easily confused
with other illnesses. Early symptoms of pancreatic cancer include weight loss, a lack
of appetite, abdominal pain, and jaundice (see Appendix A for symptom details).
When pancreatic cancer is suspected, medical imaging is conducted, leading to
discovery of masses. Unfortunately, cancerous masses that are detectable via
imaging are most often at a late stage, stressing the importance of new methods that
result in earlier detection (see Appendix B for imaging technology details).
One strategy in detecting pancreatic cancer earlier is the use of biomarkers
associated with the disease (see Appendix C for additional biomarker details). A
significant hurdle in studying biomarkers for early detection is the lack of samples
collected before diagnosis. While samples from healthy controls or patients
diagnosed with pancreatic cancer are helpful, samples collected from those prior to
a pancreatic cancer diagnosis are preferred (O'Brien, et al., 2015).
At the moment, the most commonly used biomarker associated with pancreatic
cancer is carbohydrate antigen 19-9 (CA19-9). CA19-9 has a sensitivity that varies
between 69%-98% and a specificity between 46%-98%. In a study using the serum
samples of women participating in an ovarian cancer study, but who were later
diagnosed with pancreatic cancer, O’Brien et al. found strong evidence that CA199, as well as the other proteins CA125, CEACAM1, and REG3A could play a
significant part in early pancreatic cancer diagnosis. In the study, serum samples that
were collected < 12 months before diagnosis, CA19-9 was found to have a median
level of 43.2 U/mL compared to the control sample median of 3.1 U/mL (O'Brien,
et al., 2015). O’Brien et al. grouped their data sets by time to diagnosis and found
4

CA19-9 to be significantly higher in PDAC cases when compared to the control in
the 0-0.5, 1-2, and 2-3, and 3+ year groups (O'Brien, et al., 2015). While most CA199 levels were most significant within 12 months of diagnosis, O’Brien et al. found
two cases with adequate longitudinal samples where an increase in CA19-9 levels
was detectable 3 years prior to diagnosis of PDAC (O'Brien, et al., 2015).
One of the issues with CA19-9 is that it can be found in benign and malignant
gastrointestinal tumors, making it not specific to pancreatic cancer. Another issue
with CA 19-9 is that nearly 10% of the population has trouble producing the protein
(Gharibi, Adamian, & Kelber, 2016). However, a certain level of CA 19-9 detected
in a blood sample could aid in the diagnosis of pancreatic cancer. Because CA 19-9
is not tumor specific, it is not enough of a tool to be used alone to confirm diagnosis
of pancreatic cancer. CA 19-9 is predominantly used in the management of
pancreatic cancer post diagnosis, due to its correlation to the disease, however
research in the levels of CA 19-9 in the years leading up to the disease show promise
(O'Brien, et al., 2015).
Although progress is being made in diagnosing pancreatic cancer a year or two in
advance, it is believed that it takes well over a decade before pancreatic cancer fully
develops (Gharibi, Adamian, & Kelber, 2016), providing a large window for early
detection. Finding prevalent and precise biomarkers is a challenge and many
researchers are studying new ways to detect these proteins. Because CA19-9 alone
is not a strong enough indicator of pancreatic cancer, detection could be improved
by coupling CA19-9 with other proteins that could be obtained through serum
samples.

5

Discovering New Biomarkers
Proteomics is a methodology used to find new biomarkers because of its ability to
measure protein and post-translational changes in protein levels. Gharibi et al. cites
a study where protein levels were derived from cells extracted from primary and
metastatic tumors sites. Using proteomics, the study found 547 proteins that were
unique to the primary tumor site and 487 unique to the metastatic tumors. Of these
proteins, 134 were found to have significantly higher levels between the two sites.
Focusing on these proteins may provide insight on metastasis and could be useful in
research in developing new therapies. One of the challenges of proteomics is
separating the cancerous tissue from the surrounding microenvironment.
Secretomics, a division of proteomics, is the analysis of protein secretions of cells.
Gharibi et al. discusses one study that analyzed the secretome of pancreatic cells and
found 145 secreted proteins that were 1.5 times more upregulated in pancreatic
cancer cells than healthy cells. Another secretomic study used mass spectrometry to
find that glypican-1 (GPC1), a cell-surface protein, is significantly more abundant
on pancreatic cancer derived exosomes than those of a healthy control. The study
compared GPC-1 to CA 19-9 as a biomarker and found that CA19-9 had high levels
in both benign pancreatic related diseases and PDAC, while GPC-1 exosome levels
were high in only PDAC cases (Gharibi, Adamian, & Kelber, 2016) (See Appendix
D for additional details regarding discovering new biomarkers).

Circulating Tumor Cells
Circulating tumor cells are another potential biomarker that have garnered attention
from researchers. One study aimed to identify the KRAS mutation in CTCs derived
from pancreatic cancer patients. Researchers were able to identify mutations of the
6

KRAS gene in CTCs from 11 out of 12 pancreatic cancer patients, while not finding
any mutant KRAS sequences in the hematopoietic cells from the same set of patients
(Court, et al., 2016). Court et al. came to the conclusion that a minimum of 10 CTCs
is necessary to conclude KRAS mutations are present. When <10 CTCs were
acquired, they found a significant drop in the detection of KRAS mutations. Using
Sanger sequencing to emulate clinical sequencing, Court et al. found that WGA
(whole genome amplification) was responsible for most sequencing cases that
resulted in failure and found an ADO (allele drop-out) rate of 85% (Court, et al.,
2016). However, detecting CTCs in the bloodstream is challenging because of the
low level of CTCs in blood samples. It is believed that a range of 1-50 CTCs is
contained in a 7.5 mL blood sample. A 7.5 mL blood sample is believed to have
more than a million white blood cells, requiring tests to have very high sensitivity
and specificity in order to recognize CTCs (Court, et al., 2016). Studies have found
one CTC cell per 109 hemocytes in a blood sample of a cancer patient (Qi, et al.,
2018). Of all the CTCs that break away from the primary tumor, it is believed that
.01% form into metastases. However, CTCs still have the potential of being excellent
biomarkers of cancer progression and novel techniques are being developed to detect
these cells (see Appendix E for additional CTC details).

Genomic Biomarkers
While detecting CTCs successfully depends on the level of CTCs in a sample, serum
samples can potentially give researchers access to a battery of different cancerous
cellular samples such as cell-free nucleic acid (cfNA), which includes cell-free DNA
(cfDNA) and cell-free RNA (cfRNA). These cfNAs are rich with useful information
regarding somatic mutations, cancer associated DNA methylation, and more. A
study in 1998 found that cfDNA circulating in blood varied between healthy controls
7

and those diagnosed with pancreatic cancer (Giacona, et al., 1998). The
concentration of cfDNA was found to vary between different types of pancreatic
cancer and varied at different stages of the same cancer (Qi, et al., 2018). Mutations
of genes associated with pancreatic cancer could also be seen in the cfDNA. One
study analyzed 54 genes that were common in PDAC patients and found that 90%
of mutations associated with the genes found in the biopsies of tumors were also
seen in the cfDNA, leaving researchers to believe that cfDNA could be detected with
high specificity and sensitivity (Zill, et al., 2015). Detection of KRAS mutations
have been found in the plasma of nearly 50% of PDAC patients, while almost no
mutations were found in the plasma of healthy donors, leading researchers to believe
KRAS mutations in ctDNA to be a potential viable biomarker (Qi, et al., 2018). One
type of cfNA, miRNA (microRNA) has the specificity and sensitivity to be a
pancreatic cancer biomarker. One study found that by combining miR-196a and
miR-196b, a sensitivity of 100% and specificity of 90% were achieved in detecting
pancreatic cancer. Another study found the saliva sample of pancreatic cancer
patients to have specific miRNA that were notably upregulated while another study
found stool samples of PDAC patients to have higher levels of specific miRNA
compared to those of a normal control (Qi, et al., 2018) (see Appendix F for
additional details regarding genomic biomarkers).

Sequencing
Sequencing technology is commonly utilized to classify gene mutations. Following
sequencing, techniques such as Mutation Significance of Covariance (MutSigCV)
are performed to discover mutations (Gharibi, Adamian, & Kelber, 2016). Analyzing
pancreatic tumor cells with MutSigCV resulted in 24 notably mutated genes that
were found in >3.5% of cases. While some of these mutations were already known
8

to be associated with PDAC, several novel genes were also identified (Gharibi,
Adamian, & Kelber, 2016). While highly useful, the technology used to sequence
DNA can be imprecise if the DNA being analyzed consists of homopolymer regions
and irregular guanine/cytosine (GC) content (Yeo, et al., 2012) (Benjamini & Speed,
2012) (see Appendix G for additional sequencing details).

Machine Learning Applications
The advances in computing power and access to cancer related genomic data have
led to new studies involving data analysis of genomic data and other biomarkers to
aid in the classification of different types of cancer. Way et al. investigated a
machine learning approach attempting to classify genes involved in the activation of
the Ras pathway (Way, et al., 2018). The classifier used in their experiment had an
area under the receiver operating characteristic curve (AUROC) greater than 84%
and an area under the precision recall curve (AUPR) greater than 63%. When testing
the classifier on non-training data, the predictions resulted in a AUROC of 75.2%
and a AUPR of 24.7%, indicating that the classifier was able to classify Ras
activation signals without being exposed to the associated tissues during training
(Way, et al., 2018). Way et al. also attempted to classify Ras mutations by applying
their classifier to the RNA sequences of 737 cell lines obtained from the Cancer Cell
Line Encyclopedia. Their classifier resulted in 357 out of 393 cell lines being
correctly classified as wild-type RAS and 153 out of 344 cell lines being correctly
classified as mutated Ras (See Appendix H for additional details).
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Remaining Technical Gaps
The capability to predict a disease as complicated as pancreatic cancer may depend
on additional factors besides a precise and reliant biomarker. These additional
factors could be diverse and derived from various sources. Such information is likely
to be inaccurate, incomplete and imprecise to varying degrees. Statistical data by
nature can be flawed due to biases or subjective focus of those in charge of collecting
the data. Currently, demographics of those at highest risk are based on age and
ethnicity, resulting in a broad population of individuals, where only a small subset
will eventually be diagnosed. Besides age and ethnicity, statistical data does not
provide precision to diagnose a patient in such a wide population. Also, because the
disease is diagnosed late, there is limited statistical data of patients collected prior to
diagnosis, leaving insufficient useful data to work with. As a result, a sophisticated
mathematical calculus is needed to represent and reason from imperfect information.
The belief function (BF) and evidential reasoning calculi facilitates representing and
reasoning from imperfect and diverse information in a way that is more flexible and
less limiting than traditional probabilistic and statistical methods (Lowrance, et al.,
1991). Belief functions and evidential reasoning can be regarded as a generalization
of traditional probabilistic methods. Information that has the potential of being
imperfect yet still useful for a pancreatic cancer prediction could include biopsy
location, sequencing technology used, an individual’s habits such as diet and
smoking, the amount of genetic material collected and more. The work described in
this report begins to bridge this technical gap by demonstrating the viability of an
evidence-based approach toward representing and reasoning from diverse and
imperfect pancreatic cancer related data and information.
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APPROACH
As reported by Gharibi et al., it is believed that pancreatic cancer develops in the
body for nearly 10 years before symptoms present themselves. However, current
diagnostic methods are not designed for early detection that might result in prompt
treatment that increases the probability of survival. Even though the genes and
mutations correlated with the disease are known, there currently are no serum based
diagnostic methods that detect these mutations with sufficient diagnostic fidelity.
The capability to precisely detect mutation combinations early might provide
sufficient time for effective treatments to be applied. Individuals who are at higher
risk for developing pancreatic cancer, whether through genetic disposition or
through risk factors such as smoking or drinking, currently have no options for
screening to detect the disease before metastasis. With more cancer related genomic
data becoming available, data analysis techniques of predicting cancer is a growing
area of interest. However, most genomic data analysis approaches rely solely on the
output of a machine learning algorithm to make a final classification or prediction.
The experiment conducted by Way et al. had fruitful results but did not consider
other crucial evidence that could help support or challenge results (Way, et al.,
2018). The approach undertaken in this project is to use the output of a machine
learning model as one input to be combined with other factors, such as family history
and health-risk habits, before making a final decision. This approach of combining
evidence is especially useful when using imperfect data that is often irregularly
distributed, consists of uneven class cases, and incomplete, which is often the case
with medical related data. One factor that can be used is an individual’s smoking
history. An individual with a long smoking history is five to six times more likely to
develop pancreatic cancer (Pandol, Apte, WIlson, Gukovskaya, & Edderkaoui,
2012). Evidence with such a strong correlation to pancreatic cancer could be used to
11

tilt an impartial machine learning result towards a higher likelihood of pancreatic
cancer. Besides smoking history, we can also consider drinking history, which
similarly has been reported to result in a 1.5 to 6-fold increased risk in pancreatic
cancer based on dosage and extent (Gupta, Wang, Holly, & Bracci, 2010). Because
we are using genomic data, the error rates of the sequencing technology used to
obtain the genomic information can also be used as a factor. As mentioned earlier,
if an individual’s DNA SNP consists of homopolymer regions, there is an increased
likelihood in an error during the sequencing process that could impact the accuracy
of the data used to train the machine learning model. This experiment uses a
mathematical calculus that can combine diverse factors, like those described above,
and relate them to one another to help us look beyond the traditional statistical and
probabilistic techniques and potentially develop a new diagnostic method that is both
precise and timely. A variety of experiments will be conducted to help us evaluate a
null hypothesis.
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METHOD
The mathematical calculus used in this study to combine and weigh diverse and
imperfect factors before making a final decision is known as evidential reasoning.
The evidential reasoning approach does not depend on a single source of data, but
rather assigns belief to different factors to make a classification on the likelihood of
pancreatic cancer. This approach is valuable because the statistical data needed to
make a classification is often imprecise and scarce. This experiment utilizes factors
such as an individual’s family history, smoking history, drinking history, results of
a machine learning classifier, sequencing read, the type of NGS technology used to
obtain an individual’s genomic data, biopsy location, and amount of genetic material
as input to an evidential reasoning model that could output a prediction regarding an
individual’s likelihood of pancreatic cancer based on the assigned beliefs to the
factors. The pancreatic cancer evidential reasoning prediction model used in this
study is based on a network of relationships between inputs that narrow down to a
final pancreatic cancer prediction, as shown in Figure 1. Factors, or random
variables, such as an individual’s smoking history are defined as frames consisting
of propositions that are meant to delimit all possible situations in which only one can
be true at a time. These propositions could be discrete or continuous values. For
instance, a frame representing smoking history could have the following
propositions: low, medium, or high usage. Our smoking history frame should contain
all these possibilities, along with the possibility of not knowing what an individual’s
smoking history is at all, which would be represented as the disjunction of all these
possibilities (Low  Medium  High). We would build similar frames for each
random variable (ML prediction, drinking history, etc.) we intend to use as input into
our evidential reasoning model. The propositions used in this experiment are
synthesized based on data found in the NIH GDC dataset. In evidential reasoning, a
13

knowledge source assigns probabilities to propositions, contained in frames. The
assigned probabilities express the truth of the statement. The collection of frames is
called a gallery and describes what is possible. To jointly consider proposition
statements from two distinct frames, a compatibility relation, which declares which
propositions from two frames can be true at the same time, must be defined. The
compatibility relation consists of a subset of the cross product between two frames.
Using Dempster’s Rule of Combination, frames are fused together to form a new
body of evidence, which could be fused with other bodies of evidence (Yager, Liu,
Dempster, & Shafter, 2008). The result of fusing two frames is propagated through
the model, all the way to the final frame (see Appendix I for more evidential
reasoning details). Because one of our frames is a machine learning prediction of
pancreatic cancer based on an individual’s genomic data, we tested whether a
machine learning algorithm could be trained to accurately and consistently classify
pancreatic cancer using a dataset of genes and mutations associated with the disease.
Genomic data was acquired through the NIH GDC API and manipulated before
training a linear support vector classifier (SVC) (see Appendix J for additional
details regarding how the machine learning model was built).

14

ML_PREDICTION
DIS %
NGS_TECH
DIS %
SEQ_READ
DIS %

SMOKING_HISTORY

DRINKING_HISTORY

DIS %
DIS %

PC_PREDICTION

FAMILY_MED_HISTORY
DIS %

BIOPSY_LOC

DIS %

AMT_GENETIC_MAT DIS %

Figure 1. Evidential Reasoning Model
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EXPERIMENTS
The primary source of data used for this experiment was the National Cancer
Institute (NIH) Genomic Data Commons (GDC). The pancreatic project in the GDC
consists of 185 cases of which 100 cases have been confirmed as deceased. The
average number of days to death following diagnosis was 459, with a standard
deviation of 362. The longest an individual lived following diagnosis was 2182 days
and the shortest was 12 days. The experimentation in this project uses the following
hypotheses:

Ho: Will not be able to detect pancreatic cancer significantly earlier than currently possible
HA: Will be able to detect pancreatic cancer significantly earlier than currently possible

Using the NIH GDC dataset consisting of cases that did not survive the disease, an
estimated sample size can be calculated with the assumption that the survival rate
can be doubled. Using a significance level () of .05 and a power of .80, we calculate
that a sample size of 6.96 will be necessary to test Ho:

n = [(z + z)(σ) / (μ1 – μ2)]2
n = [(1.645 + 0.84)(362) / (-459 +800)]2

Our evidential reasoning model will be tested by observing how the results vary as
the propositions and their corresponding masses are changed. Depending on the
selected propositions and assigned masses, some combinations will build support for
a prediction of pancreatic cancer, while a combination of other frames will decrease
the likelihood of a pancreatic cancer prediction. For instance, combinations such as
16

a highly active smoking and drinking history and a history of cancer in one’s
personal and family medical history are expected to increase the likelihood of a
pancreatic cancer diagnosis. Another example would be a biopsy with a low amount
of genetic material taken from a region far from the pancreas is expected to lower
the likelihood of a pancreatic cancer diagnosis. The output of the evidential
reasoning experiment will be judged based on how the evidential interval supports
the expected results of such scenarios. To observe how the output of the evidential
reasoning model changes, separate experiments are conducted to demonstrate the
impact of the combination of specific inputs. All experiments will begin with the
baseline input and discount rates shown in Table II and Table III.
Table II
Baseline Propositions and Corresponding Support
Frames
ML_PREDICTION
NGS_TECH
SEQ_READ
SMOKING_HISTORY
DRINKING_HISTORY
FAMILY_MED_HISTORY
PATIENT_MED_HISTORY
BIOPSY_SITE_CELL_RESULT
AMOUNT_GEN_MATERIAL

Assigned Proposition
NOT_PC
ionTorrent
LOW_GC_x_LOW_HMR
LOW
LOW
NO_CANCER
NO_CANCER
NOT_NEAR_PAN_REG
SMALL
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Support
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5

Table III
Discount Rates and Corresponding Frames
Frames
ML_PREDICTION
NGS_TECH
SEQ_READ
SMOKING_HISTORY
DRINKING_HISTORY
FAMILY_MED_HISTORY
PATIENT_MED_HISTORY
BIOPSY_SITE_CELL_RESULT
AMOUNT_GEN_MATERIAL

Discount Rate
0.1
0.1
0.1
0.3
0.3
0.2
0.1
0.2
0.1

A discount rate is applied to each frame to either reduce the impact of that frame or
to express a lack of credibility. For instance, the NGS technology used or the amount
of genetic material are more conclusive compared to an individual’s smoking and
drinking history, which are dependent on the patient’s credibility. Therefore, a
higher discount rate is applied to the smoking and drinking history frames. The
combination of our discount rate and initial inputs results in the following baseline
output:
Belief Of Having Pancreatic Cancer Lies Between:

(0.064, 0.142) (0)|**--------|(1)

Belief Of Not Having Pancreatic Cancer Lies Between: (0.857, 0.935) (0)|--------**|(1)

Such an output shows a very high likelihood of the individual not having pancreatic
cancer. The evidential reasoning experiments are designed to test how the following
combination of random variables impact the prediction of pancreatic cancer:
 Machine learning prediction, smoking history and drinking history
 Machine learning prediction, family health history, and personal health
history
18

 Machine learning prediction, biopsy location, and amount of genetic material
 Machine learning prediction, sequencing technology utilized, and quality of
sequencing read
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EVALUATION OF RESULTS
First, the performance of the SVC classifier was determined. To gauge variance, the
SVC classifier underwent a cross validation of 5 and resulted in an accuracy of 91%.
The classifier had an average precision score of 92% and a ROC AUC score of 92%
as shown in Figure 2. and Figure 3.

Figure 2. Support Vector Classifier Precision-Recall
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Figure 3. Support Vector Classifier ROC

While our machine learning model indicates good performance, the true
performance of this classifier remains questionable due to the limited dataset size of
185 cases. When plotting the frequency of the gene mutation combinations labeled
to be pancreatic cancer, we can see a significant amount of gene mutation
combinations that only appear once and then a significant drop off, as demonstrated
in Figure 4. This stresses the importance of utilizing a larger dataset so that more
common gene mutation combinations can be found.
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Figure 4. Dataset Gene-Mutation Frequency

ER Experiment 1
The first experiment focuses on the ML (machine learning) prediction and drinking
and smoking history frames. The frames were adjusted as follows:
 Change ML Prediction from NOT_PC to PC with a mass of 0.5
Belief Of Having Pancreatic Cancer Lies Between:
(0.26, 0.375) (0)|--**------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.625, 0.739) (0)|------**--|(1)


Increase ML Prediction mass to 0.9
Belief Of Having Pancreatic Cancer Lies Between:
(0.568, 0.639) (0)|-----**---|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.361, 0.431) (0)|---**-----|(1)
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Change Smoking History frame proposition to HIGH with a mass of 0.5
Belief Of Having Pancreatic Cancer Lies Between:
(0.764, 0.822) (0)|-------**-|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.178, 0.235) (0)|-**-------|(1)



Change Drinking History frame proposition to HIGH with a mass of 0.5
Belief Of Having Pancreatic Cancer Lies Between:
(0.888, 0.929) (0)|--------**|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.07, 0.111) (0)|**--------|(1)



Change Smoking and Drinking History frame proposition to LOW with a mass
of 0.9
Belief Of Having Pancreatic Cancer Lies Between:
(0.297, 0.333) (0)|‐‐**‐‐‐‐‐‐|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.666, 0.702) (0)|------**--|(1)

 Decrease ML Prediction frame proposition mass to 0.2:
Belief Of Having Pancreatic Cancer Lies Between:
(0.056, 0.103) (0)|**--------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.896, 0.943) (0)|--------**|(1)

This experiment demonstrates that an increased belief in an individual having a
highly active smoking and drinking history supports the ML prediction of pancreatic
cancer and increases the evidential interval of belief in an individual having
pancreatic cancer. A sharp decline in the pancreatic cancer evidential interval can
be seen as the smoking and drinking history frame propositions are changed from
HIGH to LOW with a belief of 0.9, reducing support for the ML prediction.
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ER Experiment 2
The second experiment aims to demonstrate how the family and personal health
history frames are correlated to the ML prediction frame. The experiment begins
with the original baseline values and makes the follow changes:


Baseline inputs
Belief Of Having Pancreatic Cancer Lies Between:
(0.064, 0.142) (0)|**--------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.857, 0.935) (0)|--------**|(1)



Keep ML prediction frame proposition as NOT_PC with a mass of 0.5 and
change family and personal history frame propositions to CANCER with a mass
of 0.8
Belief Of Having Pancreatic Cancer Lies Between: (0.361, 0.45) (0)|---**-----|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.549, 0.638) (0)|-----**---|(1)



Change ML prediction frame proposition to PC with a mass of 0.5
Belief Of Having Pancreatic Cancer Lies Between:
(0.674, 0.758) (0)|------**--|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.242, 0.325) (0)|--**------|(1)

 Change mass in patient and family health history frames to 0.2
Belief Of Having Pancreatic Cancer Lies Between:

(0.427, 0.573) (0)|----**----|(1)

Belief Of Not Having Pancreatic Cancer Lies Between: (0.427, 0.572) (0)|----**----|(1)



Change propositions for patient and family history frames to NO CANCER with
a mass of 0.8
Belief Of Having Pancreatic Cancer Lies Between:
(0.174, 0.252) (0)|-**-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.748, 0.825) (0)|-------**-|(1)

As expected, changing the frames of personal and family health history to CANCER
with an increased mass increases the likelihood of cancer. However, the likelihood
of cancer is still low with the ML prediction proposition set to NO PC, even when
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the patient has a personal and family history of CANCER with a high mass of 0.8.
As the ML prediction frame is adjusted to support the health history frames, the
pancreatic cancer evidential interval increases from (0.361, 0.45) to (0.674, 0.758).
Similarly, as the mass for the health history frames is reduced, our pancreatic cancer
evidential interval also decreases. Once the personal and family health history
frames are both set to NO CANCER with a mass of 0.8, the pancreatic cancer
evidential interval decreases even more.

ER Experiment 3
In experiment 3 attention is shifted to the biopsy site and amount of genetic material
frames, which impact the quality of the ML prediction. If the amount of genetic
material is low, then there is a greater likelihood that there is not enough DNA
material to detect the mutations that are needed to make a credible machine learning
decision. Also, if the biopsy location originates from a region distant from the
pancreas, there might not be enough pancreas related DNA material for the SVC to
classify. The experiment begins with the same baseline as the other experiments:



Baseline input
Belief Of Having Pancreatic Cancer Lies Between:
(0.063, 0.147) (0)|**--------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.853, 0.936) (0)|--------**|(1)



Change amount of genetic material to LARGE with a mass of 0.5 and change
biopsy site and cell result to NEAR PANCREAS and REGULAR with a mass of
0.5 and ML Prediction to PC with a mass of 0.5
Belief Of Having Pancreatic Cancer Lies Between:
(0.26, 0.374) (0)|--**------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.626, 0.739) (0)|------**--|(1)
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 Change biopsy site and cell result to NEAR PANCREAS and IRREGULAR with
a mass of 0.5
Belief Of Having Pancreatic Cancer Lies Between:

(0.534, 0.653) (0)|-----**---|(1)

Belief Of Not Having Pancreatic Cancer Lies Between: (0.346, 0.465) (0)|---**-----|(1)

 Change biopsy site and cell result mass to 0.8 and amount of genetic material to
SMALL with a mass of 0.9
Belief Of Having Pancreatic Cancer Lies Between:
(0.675, 0.758) (0)|‐‐‐‐‐‐**‐‐|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.241, 0.324) (0)|‐‐**‐‐‐‐‐‐|(1)

 Change biopsy site and cell result to NOT NEAR PANCREAS and REGULAR
with a mass of 0.9
Belief Of Having Pancreatic Cancer Lies Between:
(0.141, 0.202) (0)|-**-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.797, 0.858) (0)|-------**-|(1)

This experiment demonstrates that having moderate mass for a LARGE quantity of
genetic material and a biopsy location NEAR the pancreas with REGULAR cell
results does not strongly support the ML prediction of PC. However, when the cell
result is changed to IRREGULR with a belief of 0.5, we can see the pancreatic cancer
evidential interval increase from (0.26, 0.374) to (0.534, 0.653). Furthermore, when
the amount of genetic material is changed to SMALL with a high mass of 0.9, while
the biopsy location remains NEAR the pancreas and the cell result remains
IRREGULAR with an increased mass of 0.8, the evidential interval increased further
to (0.675, 0.758), indicating that the amount of genetic material is not as significant
of a factor when compared to the biopsy location and cell result. Once the biopsy
location is changed back to NOT NEAR and cell result is changed to REGULAR,
with a high mass of 0.9, we can see the pancreatic cancer evidential interval drop
significantly.
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ER Experiment 4
The final experiment tests how the NGS technology and the quality of the
sequencing read impact the ML prediction. The expectation is that as the sequencing
reads become more error prone by having a high guanine cytosine (GC) content and
high homopolymer regions, the ML prediction becomes less reliable, resulting in a
lower evidential interval for pancreatic cancer.
The experiment begins with the same baseline:
 Baseline inputs
Belief Of Having Pancreatic Cancer Lies Between: (0.063, 0.147) (0)|**‐‐‐‐‐‐‐‐|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.853, 0.936) (0)|--------**|(1)

 Change ML prediction to PC with a mass of 0.7
Belief Of Having Pancreatic Cancer Lies Between: (0.373, 0.471) (0)|‐‐‐**‐‐‐‐‐|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.529, 0.626) (0)|-----**---|(1)

 Change sequencing read to HIGH GC HIGH HMR with a mass of 0.9
Belief Of Having Pancreatic Cancer Lies Between:

(0.206, 0.329) (0)|--**------|(1)

Belief Of Not Having Pancreatic Cancer Lies Between: (0.671, 0.793) (0)|------**--|(1)

 Change NGS tech mass to 0.9
Belief Of Having Pancreatic Cancer Lies Between:

(0.206, 0.328) (0)|--**------|(1)

Belief Of Not Having Pancreatic Cancer Lies Between: (0.671, 0.793) (0)|------**--|(1)

 Change NGS tech to ILLUMINA
Belief Of Having Pancreatic Cancer Lies Between:

27

(0.205, 0.329) (0)|--**------|(1)

Belief Of Not Having Pancreatic Cancer Lies Between: (0.67, 0.794) (0)|------**--|(1)

 Change ML prediction mass to 0.8
Belief Of Having Pancreatic Cancer Lies Between:

(0.282, 0.394) (0)|--**------|(1)

Belief Of Not Having Pancreatic Cancer Lies Between: (0.606, 0.717) (0)|------**--|(1)

 Change sequencing read to MOD GC LOW HMR with a mass of 0.9
Belief Of Having Pancreatic Cancer Lies Between:

(0.732, 0.777) (0)|-------*--|(1)

Belief Of Not Having Pancreatic Cancer Lies Between: (0.223, 0.267) (0)|--*-------|(1)

After the belief in the ML prediction input of PC is increased from 0.5 to 0.7,
resulting in an increased pancreatic cancer evidential interval, the change of the
sequencing read frame from LOW GC LOW HMR to HIGH GC HIGH HMR causes
the evidential interval to decrease from (0.373, 0.471) to (0.206, 0.329). This is
because a HIGH GC and HIGH HMR increases the likelihood of errors during our
sequencing, resulting in a ML prediction that is not as reliable. Little changes when
the NGS tech is changed from ION TORRENT to ILLUMINA or when the ML
prediction is increased from 0.7 to 0.8. Once the sequencing read is changed to MOD
GC LOW HMR with a higher belief of 0.9, our ML prediction becomes significantly
more reliable, resulting in an increase in the evidential interval to (0.732, 0.777).

We can verify the results of our experiments based on our knowledge of the
relationships between the chosen inputs. In all four experiments the evidential
reasoning model resulted in outputs that were near to what was expected.
We can hypothesize the possibility of our evidential reasoning model predicting
pancreatic cancer twice as early under the assumption that 28 out of the 185 cases in
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the NIH GDC dataset had at least 2 of the prevalent mutations in the dataset,
resulting in a positive machine learning prediction of pancreatic cancer. Using a
significance level () of .05%, a sample size of 28 and the standard deviation (362)
and mean (459) of the days to death after diagnosis from the original NIH GDC
dataset, we can calculate a z-score of 4.97 and a statistically significant p-value of
.00001. Because our p-value is less than our significance level, we can reject the null
hypothesis under such a scenario.
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CONCLUSION AND DISCUSSION
The output of the evidential reasoning model used in this experiment changed in a
manner that was expected, based on the inputs. This experiment shows that use of
an evidential reasoning model as a diagnostic tool is not out of reach. However, the
viability of this approach depends on advances in obtaining high quality pancreatic
serum samples, accessibility to powerful and accurate NGS technology, and accurate
personal medical history. Such an approach could help narrow down a wide
demographic, into a manageable population that could be observed closely and
screened annually. As machine learning continues to expand into medical
diagnostics, the integration of an evidential reasoning approach could be utilized for
other applications to improve prediction results.
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FUTURE WORK
The next phase of this project should have a focus on genomic mutations that are
classified as having a deleterious or lethal impact. According to the National Cancer
Institute, these are disease causing mutations because they increase an individual’s
predisposition to a disease and are most often inherited. The GDC database that was
utilized to obtain the test data for this experiment includes an impact label for each
mutation that is set to either significant, moderate, or deleterious. Mutations with a
deleterious impact could be queried and analyzed using the GDC API. This will
result in a more focused dataset but runs the risk of being sparse. The pancreatic
cancer genomic data used in this project was gathered through The Cancer Genome
Atlas Program (TCGA). TCGA may be the most reputable source for genomic data,
however, it is limited, with only 185 cases in the pancreatic cancer project. In order
to improve the machine learning model, it will be necessary to seek other sources of
pancreatic cancer genomic data. Also, sampling techniques should be considered to
handle imbalanced data. To continue building and improving the evidential
reasoning model, tests should be conducted using real individual health and family
history associated with the cases in the pancreatic cancer dataset, along with
information regarding the verified type of NGS technology used to obtain the
genomic data. To increase the precision of the sequencing reads input, genomic
samples should be programmatically analyzed to detect low/high GC counts and
quantity of homopolymer regions.
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APPENDIX A
Among other symptoms, intolerance to glucose is another symptom some pancreatic
cancer patients encounter (Site-specific cancer series : Pancreatic and hepatobiliary
cancer., 2012). Additional symptoms include back pain, anorexia, nausea, epigastric
bloating, heartburn, pruritus, and dysgeusia (Risch, Yu, Lu, & Kidd, 2015).
Individuals who aggressively develop atypical type 2 diabetes mellitus, who are also
thin and over the age of 50, are suspect to have pancreatic cancer (De La Cruz,
Young, & Ruffin, 2014).
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APPENDIX B
A first step for patients presenting the common symptoms associated with pancreatic
cancer is ultrasonography imaging of the abdomen. Pancreatic cancer is most often
diagnosed after detection through some visualization method such as computed
tomography (CT) and/or magnetic resonance imaging (MRI) coupled with magnetic
resonance cholangiopancreatography (MRCP), or endoscopic ultrasound (EUS).
Multi-detector (MD) row CT is widely utilized in evaluating pancreatic cancer,
however, it has a low rate of detection. Conversely, EUS has the ability to detect
small pancreatic masses with high sensitivity. If a pancreatic mass is discovered, the
patient usually undergoes EUS and fine-needle aspiration (FNA) biopsy of the mass
(De La Cruz, Young, & Ruffin, 2014). EUS is viewed as one of the highest accuracy
methods for detecting focal lesions and tumors that have a size of <=2 cm. It is
believed that EUS can detect tumors that are less than 10mm. One report found EUS
to have a sensitivity of 84% when detecting 25 small pancreatic tumors less than
10mm each (Hijioka, et al., 2017). Another study using EUS-FNA to detect
pancreatic cancer masses with a size less than 10mm in 23 patients resulted in an
accuracy of 96% (Hijioka, et al., 2017). One issue with EUS is its tendency to
overlook a pancreatic mass in individuals suffering from other pancreas related
issues such as chronic pancreatitis (Hijioka, et al., 2017). While visualization has
proven as an effective aide in the detection of pancreatic cancer, in order to increase
the survival rate, detection needs to occur before pancreatic masses can be
visualized.
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APPENDIX C
Biomarkers are proteins, antigens, and other cellular molecules that are expressed in
higher levels in the presence of a disease. Biomarkers can be obtained in a variety
of ways, the most common being biopsy of tissue or liquid serum. Traditional
biopsies of tumor tissue are common but have several limitations and most often
take place too late. Accurate liquid biopsies are a subject of interest because they are
easily repeatable and result in real time detection. The content of liquid biopsies,
such as circulating tumor cells (CTCs), cell-free nucleic acid, and exosomes, all have
potential to contribute to the detection of pancreatic cancer (Qi, et al., 2018).
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APPENDIX D
With proteomics, one approach is to compare the healthy tissue and tumor tissue of
individuals diagnosed with pancreatic cancer, in order to find differences in global
protein levels. A higher or lower level of a protein could potentially indicate whether
the protein plays a part in tumor growth or suppression. Another approach is to
compare the protein levels in primary and metastatic tumors, in hopes of finding
proteins that play a role in metastasis (Gharibi, Adamian, & Kelber, 2016).
Secretomics focuses on secreted proteins that are involved in cell signaling and the
dissemination of tumor cells. Secretome samples can be obtained via cancerous
pancreatic cells. Secretome proteins can be identified using a mass spectrometry
approach known as stable isotope labeling with amino acids in cell culture (SILAC)
(Gharibi, Adamian, & Kelber, 2016). Another option is to examine the exosomes
derived from tumor tissue. Exosomes are vesicles that store the nucleic acid and
proteins that are secreted by cells. Inspecting the contents of cancer exosomes could
reveal information about the proteins that play a role in metastasis.
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APPENDIX E
Circulating tumors cells (CTCs) are promising traceable components of cancer.
CTCs are cells that originate from a primary tumor but break away and circulate in
the bloodstream. These cells are a subject of interest because they can enter the
bloodstream during early stages, as tumors form. It is believed that the number of
CTCs in a blood sample is correlated to the stage of tumor development (Qi, et al.,
2018). One approach to detecting CTCs is to use antibodies against antigens that are
located on the surface of the CTCs. CTCs can be detected by using epithelial cell
adhesion molecule (EpCAM) as a marker (Gharibi, Adamian, & Kelber, 2016).
Because carcinoma and epithelial cells commonly express EpCAM, while healthy
blood cells do not, the presence of EpCAM can separate CTCs from otherwise
healthy blood cells (Man, Wang, & Kemmner, 2011). CellSearch (Veridex), an FDA
approved method, utilizes ferrofluids that are developed with EpCAM to catch
CTCs. A study using this method found that CTCs related to prostate and breast
cancer were found in higher quantity compared to CTCs related to pancreatic cancer.
The CTCs that were found to be associated with pancreatic cancer had levels that
were similar to CTCs of nonmalignant diseases (Allard, et al., 2004). As a result, the
low sensitivity and EpCAM dependence makes CTC detection for pancreatic cancer
difficult. Researchers have been able to fluorescently tag and track pancreatic cancer
related CTCs in mouse models and observe the progression of cancer (Gharibi,
Adamian, & Kelber, 2016). Researchers have also found ways to deal with the low
levels of CTCs. Molecular analysis and immunocytochemistry (ICC) are methods
used to determine whether a CTC originates from a tumor (Court, et al., 2016).
However, a small number of CTCs means limited DNA is available. ICC is coupled
with whole genome amplification (WGA) to make up for the lack of DNA
microgram levels required, when only pictogram levels are available (Court, et al.,
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2016). However, one of the limitations of WGA is allele dropout (ADO) as a result
of amplification bias causing certain alleles to not be adequately amplified. Because
WGA does not provide adequate coverage of certain genes, a mutant allele could be
completely missed. These are the types of potential errors that must be taken into
account when deciding on sequencing methods (Court, et al., 2016).
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APPENDIX F
Circulating tumor DNA (ctDNA) is a unique DNA type that enters the bloodstream
through apoptosis and necrosis of tumor cells. ctDNA is also found in high
concentration in blood samples and is packed with useful information that can be
helpful in detecting tumors. A study found a high concentration of cfNA in the blood
of pancreatic cancer patients that was different from those of a healthy control (Qi,
et al., 2018). Exosomes are another type of potential biomarker that can be found in
a blood sample. Exosomes are extracellular vesicles that are secreted into circulation
by healthy and cancerous cells. Exosomes are involved in the communication of
cancer cells and their environment and can be found in blood samples earlier than
cfNA’s (Qi, et al., 2018). Exosomes can be found in significantly higher levels in
pancreatic cancer patients than healthy individuals. High levels of exosomes are due
to the extensive exosome secretion during carcinogenesis. Because exosomes are the
byproduct of the secretion of living cells, they can be found in blood when tumors
are at an early stage (Qi, et al., 2018). It is believed that serum-exosome protein
could be a viable marker for diagnosing pancreatic cancer. In one experiment, a
panel of cancer initiating proteins and miRNA that were found to be highly
expressed in the exosomes of pancreatic cancer were selected (Qi, et al., 2018). The
panel of proteins and miRNA were found to be highly regulated in the exosomes
derived from pancreatic patients, but not found in healthy patients, hinting that a
combined panel of proteins and miRNA could be used as a diagnostic tool with high
sensitivity. Because exosomes contain proteins and RNA, a study was able to
confirm that pancreatic cancer exosomes contained genomic DNA. The study found
that exosomes hold more than 10kb portions of double stranded DNA (Qi, et al.,
2018). Using genomic DNA from pancreatic cancer exosomes, KRAS and P53 gene
mutations were able to be identified, indicating that genomic data from exosomes
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obtained by serum could be used for diagnosing pancreatic cancer. Another study
found that the GPC1 protein, located in the exosome membranes, was found at a
higher concentration in 190 pancreatic cancer patients compared to healthy donors
(Qi, et al., 2018). These GPC1 proteins could be discovered before masses could be
detected through an MRI. Receiver operating curves indicate that GPC1 proteins are
an ideal biomarker with 100% specificity and sensitivity (Qi, et al., 2018).
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APPENDIX G
Sequencing is a methodology used to observe the order of nucleotide bases of the
genome or exome, enabling researchers to compare genomic and transcriptomic
variations between healthy and cancerous tissue. Knowledge of the nucleotide base
order makes classification of gene mutations possible. By identifying mutations,
therapies can be developed to target specific mutations while limiting the impact on
other cells. When testing for biomarkers, the type of NGS technology utilized along
with the type of proteomic material analyzed plays a large role. For analysis of
ctDNA/ctRNA, high coverage sequencing is necessary. In order to reduce error rates
of sequencing associated with redundancy, molecular barcodes are utilized. NGS
approaches for detecting CTCs tend to be less sensitive than digital polymerase chain
reaction (PCR) method and other approaches. However, NGS has the benefit of
checking a high volume of chromosome loci. When considering whole exome
sequencing (WES) instead of whole genome sequencing (WGS), one major
disadvantage is the inability to recognize noncoding variants and rearrangements
that have the potential to have a major impact on gene regulation. This makes a
notable difference when dealing with mutations that have the potential to be
biomarkers and are part of the regulatory and/or promoter regions. Also, WGS
related methods may obstruct detection of copy number alteration (CNA). Lastly,
the quality of each NGS method, for instance the depth of coverage, read length, and
other parameters affects the accuracy, precision, and thoroughness of sequence data
(Wesley, 2019). While NGS technology continues to advance, errors are still
common and vary with the type of NGS technology used. Illumina’s sequencing
technology is highly utilized for its ability to generate sequences with high accuracy
and throughput. It is believed that 90% of sequencing is done using Illumina.
Although Illumina is widely adopted, it is not without flaws. Illumina sequencing is
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known to have an error rate of 1-2%. Biases are also common with this kind of
sequencing. These biases include a higher concentration of errors occurring near the
end of DNA reads. Substitution errors tend to be more common than
insertion/deletion errors. Causes of error in Illumina include crosstalk, phasing,
fading, and T accumulation (Heydari, Miclotte, Van de Peer, & Fostier, 2019).
Substitution errors occur when a base is incorrectly identified and tend to take place
near the end of a sequence. Homopolymer errors occur in regions where the same
nucleotide repeats consecutively. This is also known to occur in regions where true
polymorphism occurs. Reducing these errors comes at a cost of reducing the
sensitivity of the technology (Yeo, et al., 2012). In one study that compared the
different sequencing technologies, researchers found that Illumina would result in
errors when analyzing long homopolymers that were > 20 bases. Ion Torrent, another
sequencing technology, had trouble reading homopolymer regions that were > 14
bases, nor could it accurately predict the bases in homopolymers > 8 bases (Quail,
et al., 2012). Homopolymer errors occur in regions where the same nucleotide
repeats consecutively. This is also known to occur in regions where true
polymorphism occurs. For SNP calling, a type of analysis of NGS data, researchers
found PacBio technology to be the most problematic and resulted in the least
accuracy compared to the other sequencing technologies. The accuracy of PacBio
for SNP detection was found to be 70% with nearly double the false positive rate of
the other sequencing technologies (Quail, et al., 2012).

45

APPENDIX H
Some of the most common pan-cancer mutated genes are those associated with the
Ras pathway. Mutations in the Ras pathway drive tumorigenesis and are tied to drug
resistance and low survival odds. Developing therapies for the mis-regulation of the
Ras pathway is a major goal of National Cancer Institute (Way, et al., 2018). The
Ras pathway is a route used to signal and activate genes for cell growth, division,
migration, regulation and more (Molina & Adjei, 2006). In precision oncology, an
individual’s genomic data is used to find therapies that are best suited to their
genomic make up. However, not all patients are able to be paired with a therapy.
Way et al. identifies these patients as “hidden responders” and believes their
transcriptomes could shed light on therapies they could be responsive to. To improve
the matching of these “hidden responders” with suitable therapies, Way et al.
believes classification of aberrant pathways, especially in Ras, could be a solution.
To classify, Way et al. developed a machine learning classifier that utilizes RNAseq, copy number variation, and the mutations from over 30 different types of cancer
in order to detect abnormal downstream gene expressions associated with aberrant
Ras pathway behavior (Way, et al., 2018). With these features, Way et al. is able to
not only recognize the activation of Ras, but also identify phenocopying variants and
predict the response to MEK inhibitors, which are used to target the Ras pathway.
Their classifier of choice was an elastic net penalized logistic regression model that
learned changes in pathways from gene expression acquired from biopsies of tumors
from various cancer types. Way et al. states that by using the elastic net
regularization penalty they are causing sparsity, resulting in mostly a selection of
genes associated with activation of the RAS pathway (Way, et al., 2018).
Incorporating regularization in analysis of genomic data is not uncommon. In a study
to classify SNPs associated with rheumatoid arthritis, Cho et al. applied elastic net
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regularization to address highly correlated features (Cho, Kim, Oh, Kim, & Park,
2009) in their model. Cho et al. states that elastic net regularization helped their
experiment by providing both automatic feature selection and applying continuously
shrinking coefficients and is especially helpful when the number of correlated
features outnumber the sample size.
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APPENDIX I
For each random variable in our evidential reasoning model, a frame is constructed
which declares the frame name, the data type (discrete or continuous), the possible
propositions, the parent frames that the current frame originates from, the resulting
frame that the current frame plugs into, and the compatibility relations of the frame.
Frames are defined in a text file referred to as the gallery. A mass distribution file is
created containing the masses assigned to the propositions in each frame. For
instance, if we are 90% certain an individual had a history as a highly active smoker,
a mass of 0.9 would be assigned to the HIGH smoking proposition. Another file
assigns a discount rate to each frame with the purpose of either reducing the impact
of a frame or to imply a notion of inaccuracy or lack of credibility. These text files
are used as input into the program Capri that handles the relationships between
frames and the fusing, using Dempster’s Rule. The output is an evidential interval
that indicates the minimum belief and maximum justifiable belief in the propositions
listed in the final output frame.
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APPENDIX J
To obtain data to train our machine learning model, a custom program was created
to query the desired percentage of the most prevalent genes and associated mutations
from the TCGA-PAAD pancreatic project in the GDC database. This program
retrieved all the cases from the GDC pancreatic project, along with cases from other
cancer projects that shared mutations found in the pancreatic project. The queried
GDC data was transformed by applying a permutation function to obtain all the
mutations associated with each individual case, resulting in an entry for each
possible gene mutation combination per case. If an individual in the dataset had 5
mutations, the transformation would result in 25 different entries of mutation
combinations, as shown in Figure 5.

case_id
02dbd5fa‐e31f‐4486‐8df8‐5b851f2e92bd
02dbd5fa‐e31f‐4486‐8df8‐5b851f2e92bd
02dbd5fa‐e31f‐4486‐8df8‐5b851f2e92bd
02dbd5fa‐e31f‐4486‐8df8‐5b851f2e92bd
02dbd5fa‐e31f‐4486‐8df8‐5b851f2e92bd
02dbd5fa‐e31f‐4486‐8df8‐5b851f2e92bd
02dbd5fa‐e31f‐4486‐8df8‐5b851f2e92bd

gene
KRAS
TP53
SMAD4
KRAS‐TP53
KRAS‐SMAD4
SMAD4‐TP53
KRAS‐SMAD4‐TP53

gene_mutations
KRAS‐chr12:g.25245350C>T
TP53‐chr17:g.7675076T>C
SMAD4‐chr18:g.51065607delGT
KRAS‐chr12:g.25245350C>T‐TP53‐chr17:g.7675076T>C
KRAS‐chr12:g.25245350C>T‐SMAD4‐chr18:g.51065607delGT
SMAD4‐chr18:g.51065607delGT‐TP53‐chr17:g.7675076T>C
KRAS‐chr12:g.25245350C>T‐SMAD4‐chr18:g.51065607delGT‐TP53‐chr17:g.7675076T>C

pancreatic_cancer
1
1
1
1
1
1
1

Figure 5. Example of powerset of mutations in dataset

Depending on the percentages queried, the dataset often resulted in an imbalance of
classification labels. Before training the SVC, the dataset was balanced by removing
entries associated with a label that had a significantly higher count. A final dataset
was created consisting of columns for each unique gene mutation permutation and
the pancreatic cancer label. Each row in this dataset consisted of a unique case with
a 1 for each gene mutation column associated with the case, as shown in Figure 6.
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case_id
KRAS‐chr12:g.25245350C>T TP53‐chr17:g.7675076T>C KRAS‐chr12:g.25245350C>T‐TP53‐chr17:g.7675076T>C pancreatic_cancer
c2a1de2e‐6451‐4c95‐8ce6‐263f2b7e6eff
1
0
1
1
170bbbac‐940f‐4e1b‐b0b8‐60fa36d0fa23
0
0
0
0
3e1886a8‐2ed2‐41ee‐8b58‐10f5321ade6f
1
1
0
1

Figure 6. Example of final dataset used to train SVC

Using the dataset shown above, the correlation of each column with the pancreatic
cancer label was generated. Gene mutation columns that fell below a certain
correlation were dropped from the data set. To eliminate the possibility of feature
correlation, an L1 penalty or Lasso regularization was applied.
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